<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01530438</url>
  </required_header>
  <id_info>
    <org_study_id>08-067</org_study_id>
    <nct_id>NCT01530438</nct_id>
  </id_info>
  <brief_title>Study of Cognitive and Emotional Disorders in Amyotrophic Lateral Sclerosis</brief_title>
  <acronym>SLAMEM</acronym>
  <official_title>Cognitive and Emotional Disorders in Amyotrophic Lateral Sclerosis : Neuropsychological, Imaging and Neuropathological Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Caen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Caen</source>
  <brief_summary>
    <textblock>
      Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that involves not only&#xD;
      motor structures, as was previously thought, but also brain areas dealing with cognition as&#xD;
      well as parts of the limbic system. Clinical, imaging and pathological evidence suggests that&#xD;
      ALS and fronto-temporal dementia (FTD) have several features in common, and that these two&#xD;
      diseases could be the two ends of a pathological continuum.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives : the investigators aim to study the clinical profile and magnitude of cognitive&#xD;
      disturbances, measure brain metabolism and assess cerebral atrophy in patients with ALS. The&#xD;
      relationships between cognitive, metabolic and anatomical data will be determined by the&#xD;
      correlation method. In addition, pathological studies will be carried out in deceased&#xD;
      patients having given their consent in advance, in order to quantify the neuronal loss and&#xD;
      UBIs.&#xD;
&#xD;
      Methods : the investigators plan to recruit 60 patients with ALS, 10 patients with ALS/FTD&#xD;
      (the diagnosis of dementia will rest on clinical data and formal neuropsychological testing)&#xD;
      and 20 normal control subjects. The ALS patients will be divided into 2 subsets on the basis&#xD;
      of a preliminary neuropsychological work-up, according to the presence or absence of&#xD;
      &quot;subclinical cognitive impairment&quot; as defined by abnormal scoring on tests not meeting the&#xD;
      criteria for dementia. In a second testing session carried out at the same time, a&#xD;
      comprehensive assessment of memory, behaviour and emotional changes will be done. All&#xD;
      subjects will then undergo morphological magnetic resonance imaging (MRI), resting-state&#xD;
      functional MRI and 18-fluorodeoxyglucose positron emission tomography (18FDG-PET). Whenever&#xD;
      possible, a second testing session will be carried out 9 to 12 months later in order to&#xD;
      quantify the cognitive deterioration, if any, and to find early predictors of the evolution&#xD;
      towards dementia. In deceased patients, the location and extent of neuronal loss will be&#xD;
      determined, as well as the location and number of UBIs.&#xD;
&#xD;
      Results and clinical relevance : this study is intended to improve our knowledge of the&#xD;
      clinical phenotype of ALS, and particularly to learn more about the extent of cognitive,&#xD;
      behavioural and emotional changes in this disease. This could in turn shed some further light&#xD;
      on the relationships between ALS and FTD.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2009</start_date>
  <completion_date type="Anticipated">May 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cognitive, behavioural and emotional changes assesed with Neuropsychological tests.</measure>
    <time_frame>Between 9 and 12 mth</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>brain imaging (anatomical MRI, functional MRI, PET using 18FDG)</measure>
    <time_frame>Between 9 and 12 mth</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>ALS patients without cognitive disorders</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Amyotrophic lateral sclerosis without cognitive disorders</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ALS patients with cognitive disorders</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Amyotrophic lateral sclerosis with cognitive disorders</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ALS patients + frontal-temporal dementia</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Amyotrophic lateral sclerosis plus frontal-temporal dementia</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MRI + 18FDG-PET + neuropsychological assessments ; 18FDG performed especially for the research</intervention_name>
    <description>At T0 and T9 or 12 monts, are performed :&#xD;
Imaging : fMRI at rest and anatomical MRI&#xD;
Neuropsychological assessments : general cognitive functioning, theory of mind, executive functions ...</description>
    <arm_group_label>ALS patients + frontal-temporal dementia</arm_group_label>
    <arm_group_label>ALS patients with cognitive disorders</arm_group_label>
    <arm_group_label>ALS patients without cognitive disorders</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All participants :&#xD;
&#xD;
               -  study level &gt; 7 years&#xD;
&#xD;
               -  mother tongue : french&#xD;
&#xD;
               -  signature of the informed consent of the protocol in accord with the Comité de&#xD;
                  Protection des Personnes&#xD;
&#xD;
               -  medical, neurological, neuroradiological and neuropsychological approfondis in&#xD;
                  accord with the specific inclusion and non inclusion criteria spécifiques at each&#xD;
                  population&#xD;
&#xD;
          -  Patients ALS :&#xD;
&#xD;
               -  18 to 80 years old&#xD;
&#xD;
               -  Diagnostic defined or probable in according to the reviewed criteria of El&#xD;
                  Escorial.&#xD;
&#xD;
          -  Patients ALS / FTD :&#xD;
&#xD;
               -  18 to 8O years old&#xD;
&#xD;
               -  Diagnostic defined or probable in according to El Escorial reviewed criteria and&#xD;
                  diagnostic of frontal-temporal dementia in according to Lund et Manchester&#xD;
                  criteria.&#xD;
&#xD;
          -  Control Subjects :&#xD;
&#xD;
               -  45 to 75 years old&#xD;
&#xD;
               -  DRS ≥ 130&#xD;
&#xD;
               -  BECK &lt; 8&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  All particpants :&#xD;
&#xD;
               -  Major past history (chronic pulmonary disease, cardiac disease, metabolic,&#xD;
                  haematological, endocrinological or severe immunological, cancer) ;&#xD;
&#xD;
               -  Chronic use of alcohol or drugs ;&#xD;
&#xD;
               -  IRM contraindications&#xD;
&#xD;
        Protected adults, and persons non affiliated to social protection system won't be able to&#xD;
        participate at this study. The inclusion of the participant in another biomedical research&#xD;
        protocol(during the study or into 12 months before the inclusion) is too a non inclusion&#xD;
        criterion.&#xD;
&#xD;
          -  Patients SLA and patients SLA / FTD&#xD;
&#xD;
               -  Severe bulbar disorders&#xD;
&#xD;
               -  Severe restrictive respiratory insufficiency (VC&lt;50%) with orthopny&#xD;
&#xD;
               -  Communication disorders with motor origin (non assessable tests)&#xD;
&#xD;
          -  Control Subjects :&#xD;
&#xD;
               -  Pregnant or nursing women&#xD;
&#xD;
               -  Unability to submit at the study medical follow-up for geographic or psychiatric&#xD;
                  reasons(previous or ongoing).&#xD;
&#xD;
               -  DRS score &lt; 130&#xD;
&#xD;
               -  Depressive syndrome (BECK) ≥ 8&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laurence Carluer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Caen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Center</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurence - Carluer, hospital practitioner</last_name>
      <phone>0231064624</phone>
      <phone_ext>+33</phone_ext>
      <email>carluer-l@chu-caen.fr</email>
    </contact>
    <contact_backup>
      <last_name>Fausto - Viader, Head of department</last_name>
      <phone>0231064624</phone>
      <phone_ext>+33</phone_ext>
      <email>viader-f@chu-caen.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Laurence - Carluer, Hospital Practitioner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Center</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <study_first_submitted>February 22, 2010</study_first_submitted>
  <study_first_submitted_qc>February 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2012</study_first_posted>
  <last_update_submitted>April 8, 2014</last_update_submitted>
  <last_update_submitted_qc>April 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Amyotrophic lateral sclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorodeoxyglucose F18</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

